araag2/HINT huggingface dataset:
Clinical trial NCT02405442 (phase 2, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: andecaliximab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Ability to provide a written informed consent

          -  Females of childbearing potential must have a negative pregnancy test at screening and
             baseline

          -  Documented diagnosis of Crohn's disease with a minimum disease duration of 6 months
             with involvement of the ileum and/or colon at a minimum

          -  Moderately to severely active Crohn's disease as defined by a Crohn's Disease Activity
             Index (CDAI) total score between 220-450 (inclusive) AND with evidence of active
             disease as measured by ileocolonoscopy

          -  Within the previous 5 years, demonstrated an inadequate clinical response or
             intolerance of at least one of the following agents:

               -  Corticosteroids

               -  Immunomodulators

               -  Tumor necrosis factor-alpha (TNFα) antagonists

               -  Vedolizumab

          -  May be receiving the following drugs:

               -  Oral 5-aminosalicylate (5-ASA)

               -  Oral corticosteroid therapy

               -  Antidiarrheals for chronic diarrhea

               -  Azathioprine or 6-mercaptopurine (6-MP) or methotrexate

               -  Antibiotics for the treatment of Crohn's disease

          -  Able to comply with the dosing instructions for study drug and able to comply with the
             study visits and requirements

        Key Exclusion Criteria:

          -  Evidence of abscess at screening

          -  Extensive colonic resection (subtotal or total colectomy) or history of > 2 small
             bowel resections

          -  Ileostomy, colostomy, or symptomatic stenosis of the intestine

          -  Current use of oral corticosteroids at a dose equivalent to > 30 mg/day of prednisone

          -  Ulcerative colitis or indeterminate colitis

          -  Short bowel syndrome

          -  Stool sample positive for Clostridium difficile (C. difficile) toxin, E. coli,
             Salmonella, Shigella, Campylobacter or Yersinia

          -  Treatment with any monoclonal antibody within 4 weeks of screening

          -  History or evidence of colonic mucosal dysplasia

          -  HIV, hepatitis B, hepatitis C, or tuberculosis (TB) infection

          -  Participated in a clinical study with an investigational drug or biologic within the
             last 30 days

          -  Any chronic medical condition (including, but not limited to, cardiac or pulmonary
             disease) that, in the opinion of the investigator, would make the individual
             unsuitable for the study or would prevent compliance with the study protocol

        Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT02407756 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: dupilumab
SMILES: CCO
Eligibility criteria:

        Key Inclusion Criteria:

          1. Male or female patients ≥6 to <18 years of age with a diagnosis of 1. Atopic
             Dermatitis whose disease cannot be adequately controlled with topical medications

          2. Minimum disease severity, as defined by Investigator's Global Assessment (IGA)

               1. IGA = 3 or 4 in adolescents ≥12 to <18 year of age

               2. IGA = 4 in children ≥6 to <12 years of age

        Key Exclusion Criteria:

          1. Recent treatment (within specific time windows before the baseline visit) with
             systemic immunosuppressive agents for eg. Systemic corticosteroids, live (attenuated)
             vaccines and other investigational drugs including biologics

          2. History of any of the following infections:

               1. Any systemic infection requiring treatment within 4 weeks before the baseline
                  visit

               2. Superficial skin infections within 1 week before the baseline visit

               3. Known history of HIV infection

               4. History of seropositivity to hepatitis B or C screening tests

               5. History of clinical endoparasitosis (ie, helminthic infection) within 12 months
                  before the baseline visit, or high risk of helminthic infection, unless
                  subsequent medical assessments (e.g. stool exam, blood tests, etc.) have ruled
                  out the possibility of parasite infection/infestation

          3. History of malignancy within 5 years before the baseline visit

          4. Persistent (confirmed by repeated tests ≥2 weeks apart) elevated transaminases
             (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]) more than 3
             times the upper limit of normal (ULN) during the screening period

          5. Presence of any severe concomitant illness(es) that, in the investigator's judgment,
             would adversely affect the patient's participation in the study

          6. Presence of skin comorbidities that may interfere with study assessments

          7. Females patients who are pregnant or breastfeeding

          8. Female patients who are of reproductive potential and are sexually active, who are
             unwilling to use adequate methods of contraception
Clinical trial NCT02409368 (phase 2, status: active, not recruiting)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: nivolumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  ECOG Status: PS 0-1 & PS 2

          -  Subjects with histologically or cytologically-documented SqNSCLC

          -  Subjects must have experienced disease progression or recurrence during or after one
             prior platinum doublet-based chemotherapy regimen

          -  Subjects must have evaluable disease by CT or MRI per RECIST 1.1 criteria

          -  Subjects with treated or asymptomatic CNS metastases

          -  Prior palliative radiotherapy must have been completed at least 14 days prior to study
             drug administration

          -  Prior lines of antineoplastic therapy, including hemotherapy, hormonal therapy,
             immunotherapy, surgical resection of lesions, non-palliative radiation therapy, or
             standard or investigational agents for treatment of NSCLC, must be completed 28 days
             prior to the first dose of nivolumab

          -  Males and Females, ages 18 or older

        Exclusion Criteria:

          -  Subjects with untreated, symptomatic CNS metastases

          -  Subjects with carcinomatous meningitis

          -  Subjects with active, known or suspected autoimmune disease.

          -  Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2,
             anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or
             drug specifically targeting T-cell costimulation or checkpoint pathways) or who have
             previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab.
Clinical trial NCT02410200 (phase 2, status: completed)
Conditions: multiple sclerosis, relapsing-remitting
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: dimethyl fumarate
SMILES: [H]\C(=C(\[H])C(=O)OC)C(=O)OC
Eligibility criteria:

        Key Inclusion Criteria:

          -  Ability of parents or legal guardians to understand the purpose and risks of the study
             and provide signed and dated informed consent and authorization to use protected
             health information in accordance with national and local subject privacy regulations.
             Subjects will provide assent in addition to the parent or legal guardian, as
             appropriate, as per local regulations.

          -  Must have a body weight of ≥30 kg at Screening and Day 1.

          -  Must have a diagnosis of RRMS according to McDonald criteria for MS (2010) [Polman
             2011] and International Pediatric Multiple Sclerosis (MS) Study Group criteria for
             pediatric MS (2013) [Krupp 2013].

        Key Exclusion Criteria:

          -  Primary progressive, secondary progressive, or progressive relapsing MS (as defined by
             [Lublin and Reingold 1996]). These conditions require the presence of continuous
             clinical disease worsening over a period of at least 3 months. Subjects with these
             conditions may also have superimposed relapses but are distinguished from
             relapsing-remitting subjects by the lack of clinically stable periods or clinical
             improvement.

          -  Disorders mimicking MS, such as other demyelinating disorders (e.g., acute
             disseminated encephalomyelitis), systemic autoimmune disorders (e.g., Sjögren disease,
             lupus erythematosus, and neuromyelitis optica), metabolic disorders (e.g.,
             dystrophies), and infectious disorders.

          -  History of severe allergic or anaphylactic reactions or known drug hypersensitivity to
             dimethyl fumarate or fumaric acid esters.

        NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT02412020 (phase 2, status: completed)
Conditions: refractory chronic cough
ICD codes: D46.4, D46.1, D46.A, D46.0, D46.20, D46.21, D46.22
Drugs: pa101, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Idiopathic Pulmonary Fibrosis (based on presence of definitive or
             possible usual interstitial pneumonia UIP pattern on high-resolution computed
             tomography and after excluding lung diseases associated with environmental and
             occupational exposure, with connective tissue disease and with drugs; transfer
             capacity for carbon monoxide corrected for hemoglobin [TLCOc] >25% predicted within 12
             months of Screening; and forced vital capacity [FRC] >50% predicted within 1 month of
             Screening) or Chronic Idiopathic Cough (that is unresponsive to targeted treatment for
             identified underlying triggers including post-nasal drip, asthmatic/non-asthmatic
             eosinophilic bronchitis, and gastro-esophageal reflux disease)

          -  Refractory chronic cough for at least 8 weeks

          -  Daytime cough severity score >40 mm on Cough Severity VAS at Screening

          -  Daytime average cough count ≥15 per hour at Screening

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Current or recent history of clinically significant medical condition, laboratory
             abnormality or illness that could put the patient at risk or compromise the quality of
             the study data as determined by the investigator

          -  Upper or lower respiratory tract infection within 4 weeks of Screening

          -  History of malignancy treated or untreated within the past 5 years, with the exception
             of localized basal cell carcinoma or cervix carcinoma in situ

          -  Current or recent history (within 12 months) of excessive use or abuse of alcohol

          -  Current or recent history (within 12 months) of abusing legal drugs or use of illegal
             drugs or substances

          -  Participation in any other investigational drug study within 4 weeks of Screening

          -  Use of prednisone, narcotic antitussives, baclofen, gabapentin, inhaled
             corticosteroids, benzonatate, dextromethorphan, carbetapentane, H1 antihistamines,
             leukotriene modifiers, and cromolyn sodium within 2 weeks of Screening

          -  Pregnant or breastfeeding females, or if of child-bearing potential unwilling to
             practice acceptable means of birth control or abstinence during the study
Clinical trial NCT02412852 (phase 2, status: completed)
Conditions: diabetes
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: sodium nitrite, placebo
SMILES: [O-]N=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female subjects must be post-menopausal, sterilized or using suitable birth control

          -  Diagnosis of diabetes (HbA1c > 6.0)

          -  Diagnosis of diabetic peripheral neuropathy pain in feet

          -  Presence of ongoing diabetic neuropathic for at least 3 months

          -  A pain score of greater than or equal to 4 on the Numerical Pain Rating Scale at
             screening

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Patients with fibromyalgia or regional pain caused by lumbar or cervical compression

          -  History or diagnosis of significant neurological disease

          -  History and diagnosis of clinically significant psychiatric diseases

          -  Serious liver disease

          -  Poorly controlled diabetes

          -  Hypersensitivity to sodium nitrite or related compounds

          -  Life expectancy < 6 months

          -  A chronic illness that may increase the risks associated with this study

          -  Active malignancy requiring active anti-neoplastic therapy that will, in the opinion
             of the investigator, interfere with study treatment or participation

          -  Pregnant or nursing women

          -  Current diagnosis of alcohol or other substance abuse

          -  Current use of sildenafil or other phosphodiesterase Type 5 Inhibitors

          -  History of methemoglobinemia, (met-Hb ≥ 15%)

          -  Subject is involved in litigation or receives worker's compensation

          -  Inability to speak English
Clinical trial NCT02413372 (phase 2, status: completed)
Conditions: non-alcoholic steatohepatitis
ICD codes: K75.81
Drugs: bms-986036, bms-986036, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Male or female between 21 and 75 years old

          -  Body Mass Index (BMI) of 25 or more

        Exclusion Criteria:

          -  Chronic Liver disease other than NASH

          -  Uncontrolled diabetes

          -  Any major surgery within 6 weeks of screening

          -  Unable to self-administer under the skin injections

          -  Any bone trauma, fracture or bone surgery within 8 weeks of screening
Clinical trial NCT02415595 (phase 2, status: terminated)
Conditions: infection, human immunodeficiency virus
ICD codes: Z21
Drugs: bms-955176, efv, tdf/ftc
SMILES: FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Reason stopped: 
    the trial ended early due to gi intolerability and treatment-emergent resistance.
  
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Men and non-pregnant women, at least 18 years of age

          -  Antiretroviral treatment-naïve; defined as no current or previous exposure to > 1 week
             of an antiretroviral drug

          -  Plasma HIV-1 RNA ≥ 1000 copies/mL

          -  CD4 T-cell count > 200 cells/mm3

        Exclusion Criteria:

          -  Resistance or partial resistance to any study drug determined by tests at Screening

          -  Current or historical genotypic and/or phenotypic drug resistance testing showing
             certain resistance mutations to EFV, TDF, FTC, Protease Inhibitors

          -  Chronic hepatitis B virus (HBV)/ hepatitis C virus (HCV)

          -  Blood tests that indicate normal liver function

          -  Hemoglobin < 8.0 g/dL, platelets < 50,000 cells/mm3
Clinical trial NCT02415829 (phase 2, status: unknown status)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine plus oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Performance status (ECOG) 0~2

          2. Histologically confirmed colon cancer.

          3. No prior treatment

          4. CT-defined T4 or lymph node-positive colon cancer

          5. Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 8 g/dL Bilirubin
             level ≤ 1.0 x ULN

          6. AST and ALT < 1.5 x ULN

          7. Serum creatinine ≤ 1.0 x ULN

          8. Life expectancy of ≥ 3 months

          9. Signed written informed consent

        Exclusion Criteria:

          1. Final stage with cancer cachexia

          2. Allergy for capecitabine or oxaliplatin

          3. Any evidence of extrahepatic metastases and/or primary tumor recurrence

          4. Severe organ failures or diseases, including: clinically relevant coronary disease,
             cardiovascular disorder or myocardial infarction within 12 months before study entry,
             severe psychiatric illness, severe infection and DIC
Clinical trial NCT02418754 (phase 2, status: terminated)
Conditions: neovascular age-related macular degeneration
ICD codes: H35.3211, H35.3212, H35.3221, H35.3222, H35.3231, H35.3232, H35.3291
Drugs: regn2176-3, intravitreal aflibercept injection (iai)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    no additional efficacy seen with regn2176-3 over aflibercept alone
  
Eligibility criteria:

        Key Inclusion Criteria:

          1. Men or women ≥50 years of age

          2. Active subfoveal CNV secondary to AMD as evidenced by FA in the study eye, as
             determined by the reading center, including juxtafoveal lesions that affect the fovea

          3. BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye at the
             screening visit

          4. Provide signed informed consent

        Key Exclusion Criteria:

          1. Any prior treatment with anti-VEGF treatment in the study eye

          2. Any prior treatment (ie, systemic or ocular treatment) with PDGF or PDGFR inhibitors

          3. Dense fibrotic scar or atrophy in the study eye involving the center of the fovea

          4. Presence of retinal pigment epithelial tears or rips involving the macula in the study
             eye

          5. Prior vitrectomy in the study eye

          6. Any history of macular hole of stage 2 and above in the study eye

          7. Any intraocular or periocular surgery within 3 months of day 1 in the study eye,
             except lid surgery

          8. History of corneal transplant in the study eye

          9. Evidence of diabetic retinopathy or diabetic macular edema in either eye

         10. Positive serum human chorionic gonadotropin/urine pregnancy test at the screening or
             baseline visit
Clinical trial NCT02423122 (phase 2, status: completed)
Conditions: alzheimer's disease, mild cognitive impairment
ICD codes: G30.8, G30.9, G30.0, G30.1, G31.84
Drugs: vx-745
SMILES: FC1=CC(F)=C(SC2=NN3C=NC(=O)C(=C3C=C2)C2=C(Cl)C=CC=C2Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to provide informed consent

          -  Diagnosis of mild cognitive impairment (MCI) due to probable AD or of mild AD

          -  MMSE range: 20 to 28

          -  Evidence of amyloid pathology by amyloid PET scan

          -  Participants may be taking medications for AD, provided that the dose of these
             medications has been stable for >3 months

          -  Proficiency in Dutch and adequate visual and auditory abilities to be able to perform
             all aspects of the cognitive and functional tests

          -  Adequate visual and auditory abilities to perform all aspects of the cognitive and
             functional assessments.

        Exclusion Criteria:

          -  Evidence of neurodegenerative disease other than AD

          -  Inability for any reason to undergo PET and fMRI scans (including notably: history of
             allergic reaction of any severity to 11C-PiB injection; pacemaker, vascular stent or
             stent graft)

          -  Psychiatric disorder that would compromise ability to comply with study requirements

          -  Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune
             disorder or metabolic/endocrine disorders or other disease that would preclude
             treatment with p38 MAP kinase inhibitor and/or assessment of drug safety and efficacy

          -  Recent (<90 days) changes to AD medications prescribed for cognitive reasons or with
             the potential to impact cognition

          -  Participation in a study of an investigational drug less than 6 months or 5 half-lives
             of the investigational drug, whichever is longer, before enrollment in the study

          -  Male subjects with female partner of child-bearing potential who are unwilling or
             unable to adhere to contraception requirements

          -  Female subjects who have not reached menopause or have not had a hysterectomy or
             bilateral oophorectomy/salpingoophorectomy

          -  Positive urine or serum pregnancy test or plans desires to become pregnant during the
             course of the trial

          -  Any factor deemed by the investigator to be likely to interfere with study conduction